glp 1 anti obesity GLP-1 anti-obesity medicines remain too expensive GLP−1 receptor agonists for the

GLP-1 medications (glucagon-like peptide-1 agonists) have blown up in popularity in the last few years

Full analysis #GLP1 #EmployeeBenefits #HealthcareCosts #WorkforceHealth #Aon Farheen Dam Doug Melton Lisa Stevens Laura Rissover Liz Parr Lindsay Dower, MHA Kembre Roberts, PhD Workforce-Focused Analysis on GLP-1s: Phase Two Findings aon.com To view or add a comment, sign in Novo Nordisks FDA-approved Wegovy pill, as highlighted by Ferrin Williams, PharmD MBA, marks a major shift in obesity careintroducing an oral GLP-1 option that could expand access, improve adherence, and reshape how clinicians manage chronic weight conditions

More serious side effects, such as pancreatitis or gallbladder issues, are rare but should be discussed with your healthcare provider before starting treatment

Calorie Deficit: What to Know Doherty, R., Madigan, S., Nevill, A., Warrington, G., & Ellis, J

Science 286 , 711715 (1999)